Non-invasive Prenatal Testing Market Size was valued at USD 3.4 billion in 2021 and is projected to reach USD 6.5 billion by 2028 at a CAGR of 9.8% during the forecast period 2022 to 2028. Noninvasive prenatal testing is a new type of genetic testing that is used to screen birth defects and inherited diseases. This test is also known as the cell-free DNA screening. The procedures include both non-invasive techniques and invasive techniques. In non-invasive techniques, serum screening and ultrasonography are included. Whereas, in invasive techniques amniocentesis and chorionic villus sampling are included. Most of the healthcare professionals prefer the non-invasive techniques over invasive, as the invasive techniques have higher risk quotient, also sometimes leads to fetal loss. Noninvasive prenatal testing are the innovative testing procedures that uses cell-free circulating fetal DNA in the maternal serum to screen for more common fetal aneuploidies, such as trisomy 21, trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). Increasing prevalence of these genetic disorders are likely to drive the market for non-invasive prenatal testing over the forecast period. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. The major market participants are adopting the strategies such as mergers and acquisitions to position themselves as strong players. In February 2018, BD (Becton, Dickinson and Company) announced the commercial availability of the CE-IVD marked PAXgene Blood ccfDNA tube within the European Economic Area and Switzerland (Western Europe).